Sensei Biotherapeutics Inc

Item 5. Other Information.

During the three months ended March 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any contracts, instructions or written plans for the purchase or sale of our securities.

Appointment of John Celebi as Principal Financial Officer and Principal Accounting Officer

On May 7, 2024, our board of directors appointed John Celebi, our Chief Executive Officer, as our principal financial officer and principal accounting officer, effective as of such date. The board of directors appointed Mr. Celebi to serve as our principal financial officer and principal accounting officer until the day after the filing of this Report. Biographical information for Mr. Celebi is available in our proxy statement filed with the Securities and Exchange Commission on April 29, 2024 in connection with our 2024 annual meeting of stockholders, such information being incorporated herein by reference.

Appointment of David Gaiero as Principal Financial Officer and Principal Accounting Officer

On May 7, 2024, our board of directors appointed David Gaiero as our principal financial officer and principal accounting officer, effective as of the day after the filing of this Report.

Mr. Gaiero, age 46, currently serves as a partner with Monomoy Advisors, LLC ("Monomoy Advisors"), a financial advisory services firm. Mr. Gaiero served as Chief Financial Officer of Cyteir Therapeutics, Inc. from January 2023 to May 2024 and previously as their Vice President of Finance from December 2020 until January 2023. Prior to joining Cyteir, Mr. Gaiero served in various roles at Wave Life Sciences from 2017 to 2020, most recently serving as Interim Chief Financial Officer and prior to that, serving as Vice President and Corporate Controller. Prior to joining Wave, from 2015 to 2017, Mr. Gaiero served as Vice President and Corporate Controller of OvaScience, Inc. Prior to that, Mr. Gaiero held various positions of increasing responsibility and scope in finance and accounting at iRobot Corporation. Mr. Gaiero began his career in public accounting at PricewaterhouseCoopers LLP. Mr. Gaiero received a B.B.A. in Accounting from the University of Massachusetts, Amherst, and is a Certified Public Accountant in Massachusetts.

In connection with Mr. Gaiero's appointment as our principal financial officer and principal accounting officer, we amended an existing services agreement with Monomoy Advisors, pursuant to which Mr. Gaiero will be made available to us on a part-time basis at the rate of $13,000 per month. Under the amended services agreement, Mr. Gaiero will fulfill duties and responsibilities typical of an interim Chief Financial Officer. The foregoing description of the amended services agreement is not complete and is qualified in its entirety by reference to the services agreement, as amended, which is filed herewith as Exhibit 10.4 and incorporated by reference herein.

The selection of Mr. Gaiero to serve as principal financial officer and principal accounting officer was not pursuant to any arrangement or understanding between him and any other person. Mr. Gaiero has no family relationship with any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.